Abstract
Brain metastases from non-small cell lung cancer develop in approximately one-third of patients. If not treated, neurological deterioration occurs quickly. Treatment with whole brain irradiation is advisable to palliate symptoms but despite this treatment, survival remains poor at 3-6 months. Recently, aggressive approaches with surgical resection and stereotactic radiosurgery have dramatically improved the control of brain metastases resulting in a meaningful survival advantage for a subset of eligible patients. New evidence also suggests a possible role for chemotherapy in the treatment of brain metastases. With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category. Copyright (C) 1998 Elsevier Science Ireland Ltd.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 85-91 |
| Number of pages | 7 |
| Journal | Lung Cancer |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1998 |
| Externally published | Yes |
Fingerprint
Keywords
- Brain metastases
- Non-small cell lung cancer
- Treatment
ASJC Scopus subject areas
- Oncology
Cite this
Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? / Kelly, Karen; P.A. Bunn, Jr.
In: Lung Cancer, Vol. 20, No. 2, 1998, p. 85-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?
AU - Kelly, Karen
AU - P.A. Bunn, Jr
PY - 1998
Y1 - 1998
N2 - Brain metastases from non-small cell lung cancer develop in approximately one-third of patients. If not treated, neurological deterioration occurs quickly. Treatment with whole brain irradiation is advisable to palliate symptoms but despite this treatment, survival remains poor at 3-6 months. Recently, aggressive approaches with surgical resection and stereotactic radiosurgery have dramatically improved the control of brain metastases resulting in a meaningful survival advantage for a subset of eligible patients. New evidence also suggests a possible role for chemotherapy in the treatment of brain metastases. With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category. Copyright (C) 1998 Elsevier Science Ireland Ltd.
AB - Brain metastases from non-small cell lung cancer develop in approximately one-third of patients. If not treated, neurological deterioration occurs quickly. Treatment with whole brain irradiation is advisable to palliate symptoms but despite this treatment, survival remains poor at 3-6 months. Recently, aggressive approaches with surgical resection and stereotactic radiosurgery have dramatically improved the control of brain metastases resulting in a meaningful survival advantage for a subset of eligible patients. New evidence also suggests a possible role for chemotherapy in the treatment of brain metastases. With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category. Copyright (C) 1998 Elsevier Science Ireland Ltd.
KW - Brain metastases
KW - Non-small cell lung cancer
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0031904419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031904419&partnerID=8YFLogxK
U2 - 10.1016/S0169-5002(98)00020-8
DO - 10.1016/S0169-5002(98)00020-8
M3 - Article
C2 - 9711526
AN - SCOPUS:0031904419
VL - 20
SP - 85
EP - 91
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 2
ER -